| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 49 | 2020 | 358 | 6.410 |
Why?
|
| Arthritis, Experimental | 42 | 2019 | 125 | 4.920 |
Why?
|
| Proteoglycans | 59 | 2016 | 337 | 4.550 |
Why?
|
| T-Lymphocytes | 28 | 2017 | 211 | 3.420 |
Why?
|
| Aggrecans | 30 | 2019 | 146 | 2.960 |
Why?
|
| Hyaluronan Receptors | 15 | 2017 | 31 | 2.730 |
Why?
|
| Mice | 102 | 2023 | 1607 | 2.630 |
Why?
|
| Arthritis | 26 | 2017 | 107 | 2.610 |
Why?
|
| Animals | 117 | 2023 | 4552 | 2.290 |
Why?
|
| Mice, Inbred BALB C | 73 | 2017 | 263 | 2.190 |
Why?
|
| Cell Adhesion Molecules | 12 | 2012 | 40 | 1.920 |
Why?
|
| Epitopes | 15 | 2017 | 81 | 1.920 |
Why?
|
| Cartilage, Articular | 27 | 2016 | 524 | 1.720 |
Why?
|
| Hyaluronic Acid | 14 | 2017 | 94 | 1.500 |
Why?
|
| Disease Models, Animal | 37 | 2019 | 724 | 1.390 |
Why?
|
| Extracellular Matrix Proteins | 18 | 2012 | 127 | 1.330 |
Why?
|
| Citrulline | 4 | 2019 | 9 | 1.220 |
Why?
|
| Joints | 11 | 2012 | 97 | 1.030 |
Why?
|
| Cytokines | 22 | 2016 | 347 | 1.020 |
Why?
|
| Synovial Fluid | 4 | 2014 | 123 | 1.000 |
Why?
|
| Myeloid Cells | 2 | 2014 | 16 | 0.960 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 6 | 2023 | 10 | 0.910 |
Why?
|
| Antibodies, Monoclonal | 11 | 2008 | 260 | 0.900 |
Why?
|
| Cell Proliferation | 11 | 2017 | 201 | 0.890 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 55 | 0.850 |
Why?
|
| L-Selectin | 3 | 2006 | 13 | 0.820 |
Why?
|
| Lymphocyte Activation | 18 | 2014 | 209 | 0.800 |
Why?
|
| Synovial Membrane | 14 | 2012 | 81 | 0.790 |
Why?
|
| Autoimmune Diseases | 12 | 2019 | 61 | 0.780 |
Why?
|
| Cell Movement | 9 | 2012 | 105 | 0.770 |
Why?
|
| Neutrophils | 6 | 2011 | 117 | 0.720 |
Why?
|
| Leukocytes | 5 | 2012 | 43 | 0.710 |
Why?
|
| Autoantibodies | 12 | 2019 | 100 | 0.700 |
Why?
|
| Granulocytes | 3 | 2008 | 23 | 0.670 |
Why?
|
| Receptors, Thrombin | 1 | 2017 | 1 | 0.640 |
Why?
|
| Vaccines | 2 | 2017 | 12 | 0.640 |
Why?
|
| Immunity, Innate | 6 | 2014 | 90 | 0.640 |
Why?
|
| Thrombin | 1 | 2017 | 12 | 0.640 |
Why?
|
| Female | 64 | 2023 | 16197 | 0.630 |
Why?
|
| Lymphocytes | 11 | 2009 | 110 | 0.620 |
Why?
|
| Osteoarthritis | 9 | 2016 | 363 | 0.590 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2008 | 215 | 0.580 |
Why?
|
| Antigen-Presenting Cells | 3 | 2012 | 16 | 0.570 |
Why?
|
| Humans | 81 | 2019 | 29337 | 0.540 |
Why?
|
| Chemotaxis, Leukocyte | 4 | 2008 | 17 | 0.540 |
Why?
|
| Lymph Nodes | 2 | 2012 | 70 | 0.520 |
Why?
|
| Quantitative Trait Loci | 7 | 2012 | 61 | 0.510 |
Why?
|
| B-Lymphocytes | 8 | 2019 | 81 | 0.510 |
Why?
|
| Mice, Knockout | 15 | 2013 | 303 | 0.510 |
Why?
|
| Cells, Cultured | 16 | 2016 | 676 | 0.510 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 96 | 0.500 |
Why?
|
| Dendritic Cells | 3 | 2017 | 56 | 0.490 |
Why?
|
| Cartilage | 12 | 2012 | 148 | 0.480 |
Why?
|
| Antigen Presentation | 5 | 2015 | 21 | 0.470 |
Why?
|
| Thymocytes | 2 | 2023 | 2 | 0.470 |
Why?
|
| Epitopes, T-Lymphocyte | 8 | 2019 | 29 | 0.460 |
Why?
|
| Mice, Inbred DBA | 16 | 2013 | 50 | 0.450 |
Why?
|
| Mice, Transgenic | 13 | 2023 | 248 | 0.450 |
Why?
|
| Spondylitis, Ankylosing | 8 | 2009 | 44 | 0.450 |
Why?
|
| Synovitis | 3 | 2017 | 22 | 0.450 |
Why?
|
| Mice, SCID | 11 | 2014 | 55 | 0.430 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2009 | 86 | 0.430 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2013 | 441 | 0.420 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2023 | 8 | 0.420 |
Why?
|
| Leukocyte Rolling | 2 | 2008 | 4 | 0.410 |
Why?
|
| Tryptases | 1 | 2011 | 8 | 0.410 |
Why?
|
| Heparin | 1 | 2011 | 26 | 0.400 |
Why?
|
| Immunization | 13 | 2017 | 47 | 0.390 |
Why?
|
| Temporomandibular Joint | 1 | 2011 | 13 | 0.390 |
Why?
|
| Lectins, C-Type | 17 | 2005 | 106 | 0.390 |
Why?
|
| Lymphoid Tissue | 3 | 2003 | 18 | 0.380 |
Why?
|
| Signal Transduction | 8 | 2023 | 482 | 0.380 |
Why?
|
| Cell Adhesion | 7 | 2008 | 43 | 0.370 |
Why?
|
| Adoptive Transfer | 8 | 2014 | 44 | 0.370 |
Why?
|
| Immunohistochemistry | 5 | 2016 | 391 | 0.370 |
Why?
|
| Inflammation | 7 | 2017 | 344 | 0.350 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2016 | 130 | 0.350 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2023 | 29 | 0.340 |
Why?
|
| Interleukin-17 | 4 | 2016 | 27 | 0.340 |
Why?
|
| Receptors, Chemokine | 1 | 2008 | 11 | 0.340 |
Why?
|
| ADAM Proteins | 4 | 2013 | 64 | 0.330 |
Why?
|
| Interleukin-4 | 7 | 2010 | 35 | 0.320 |
Why?
|
| Autoantigens | 7 | 2019 | 36 | 0.320 |
Why?
|
| Male | 32 | 2023 | 15621 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2019 | 218 | 0.310 |
Why?
|
| Amino Acid Sequence | 9 | 2016 | 193 | 0.310 |
Why?
|
| Ankle Joint | 2 | 2005 | 39 | 0.300 |
Why?
|
| Extracellular Matrix | 4 | 2012 | 74 | 0.300 |
Why?
|
| Blotting, Western | 6 | 2016 | 170 | 0.290 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2017 | 100 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 14 | 2017 | 432 | 0.290 |
Why?
|
| Antirheumatic Agents | 2 | 2013 | 92 | 0.280 |
Why?
|
| Kinetics | 8 | 2012 | 225 | 0.280 |
Why?
|
| Flow Cytometry | 7 | 2019 | 198 | 0.280 |
Why?
|
| Endopeptidases | 4 | 2011 | 29 | 0.280 |
Why?
|
| Microscopy, Video | 1 | 2005 | 5 | 0.280 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2005 | 7 | 0.270 |
Why?
|
| Glycosaminoglycans | 4 | 2011 | 51 | 0.270 |
Why?
|
| Peptide Fragments | 6 | 2013 | 99 | 0.260 |
Why?
|
| Interferon-gamma | 8 | 2009 | 109 | 0.260 |
Why?
|
| Skin | 1 | 2005 | 117 | 0.260 |
Why?
|
| Th2 Cells | 6 | 2012 | 27 | 0.250 |
Why?
|
| Cytoskeleton | 2 | 2001 | 51 | 0.250 |
Why?
|
| Apoptosis | 7 | 2014 | 251 | 0.240 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2016 | 4 | 0.240 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2023 | 1 | 0.230 |
Why?
|
| Infertility, Female | 1 | 2003 | 19 | 0.230 |
Why?
|
| Oocytes | 1 | 2003 | 16 | 0.230 |
Why?
|
| Cytoplasm | 1 | 2003 | 35 | 0.230 |
Why?
|
| Bone Development | 1 | 2023 | 32 | 0.220 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 132 | 0.220 |
Why?
|
| Cattle | 7 | 2004 | 217 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2023 | 59 | 0.220 |
Why?
|
| Th1 Cells | 5 | 2004 | 29 | 0.220 |
Why?
|
| Tendinopathy | 2 | 2013 | 60 | 0.220 |
Why?
|
| Bone Marrow Cells | 3 | 2017 | 57 | 0.210 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2012 | 22 | 0.210 |
Why?
|
| Chondrocytes | 3 | 2011 | 197 | 0.210 |
Why?
|
| Fibroblasts | 6 | 2008 | 95 | 0.210 |
Why?
|
| Autoimmunity | 3 | 2004 | 19 | 0.200 |
Why?
|
| Adult | 14 | 2016 | 8601 | 0.200 |
Why?
|
| Down-Regulation | 2 | 1999 | 112 | 0.200 |
Why?
|
| Molecular Sequence Data | 10 | 2012 | 246 | 0.200 |
Why?
|
| Drugs, Investigational | 1 | 2000 | 8 | 0.190 |
Why?
|
| Skin Diseases | 2 | 2011 | 26 | 0.190 |
Why?
|
| Dogs | 5 | 2004 | 253 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 3 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2019 | 124 | 0.190 |
Why?
|
| Chromosomes, Mammalian | 2 | 2012 | 5 | 0.190 |
Why?
|
| Edema | 3 | 2001 | 38 | 0.190 |
Why?
|
| Major Histocompatibility Complex | 3 | 2012 | 13 | 0.180 |
Why?
|
| Spleen | 4 | 2016 | 51 | 0.180 |
Why?
|
| Azacitidine | 1 | 2019 | 10 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2019 | 638 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 145 | 0.170 |
Why?
|
| Th17 Cells | 2 | 2016 | 28 | 0.170 |
Why?
|
| Disease Progression | 5 | 2006 | 787 | 0.170 |
Why?
|
| RANK Ligand | 2 | 2008 | 7 | 0.170 |
Why?
|
| Up-Regulation | 4 | 2013 | 174 | 0.170 |
Why?
|
| Hybridomas | 7 | 2003 | 19 | 0.160 |
Why?
|
| Immune Tolerance | 2 | 2017 | 22 | 0.160 |
Why?
|
| Mutation | 4 | 2014 | 383 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2017 | 7 | 0.160 |
Why?
|
| Antibody Specificity | 3 | 2016 | 50 | 0.160 |
Why?
|
| Protein Structure, Tertiary | 2 | 2016 | 61 | 0.160 |
Why?
|
| Rats | 6 | 2013 | 854 | 0.150 |
Why?
|
| Immunization, Passive | 3 | 1995 | 20 | 0.150 |
Why?
|
| Allergens | 1 | 2017 | 22 | 0.150 |
Why?
|
| Recombinant Proteins | 6 | 2012 | 251 | 0.150 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 74 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 8 | 0.140 |
Why?
|
| Gene Expression | 4 | 2013 | 226 | 0.140 |
Why?
|
| Myocarditis | 1 | 2016 | 6 | 0.140 |
Why?
|
| Complex Mixtures | 1 | 2016 | 3 | 0.140 |
Why?
|
| Gene Silencing | 2 | 2019 | 21 | 0.140 |
Why?
|
| Tissue Extracts | 1 | 2016 | 13 | 0.140 |
Why?
|
| Arginine | 1 | 2016 | 18 | 0.140 |
Why?
|
| Organ Specificity | 2 | 2014 | 47 | 0.140 |
Why?
|
| Phenotype | 4 | 2012 | 355 | 0.140 |
Why?
|
| Spondylarthropathies | 2 | 2005 | 7 | 0.140 |
Why?
|
| Heart | 1 | 2016 | 91 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 3 | 2004 | 26 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 284 | 0.140 |
Why?
|
| Disease Susceptibility | 4 | 2012 | 80 | 0.130 |
Why?
|
| Immunoglobulin E | 2 | 2005 | 15 | 0.130 |
Why?
|
| Immunotherapy, Active | 1 | 2015 | 3 | 0.130 |
Why?
|
| Immunoglobulin G | 5 | 2005 | 129 | 0.130 |
Why?
|
| Alpha-Globulins | 2 | 2012 | 7 | 0.130 |
Why?
|
| Collagen | 4 | 1995 | 102 | 0.130 |
Why?
|
| Middle Aged | 12 | 2014 | 9823 | 0.130 |
Why?
|
| Coculture Techniques | 1 | 2014 | 37 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 64 | 0.130 |
Why?
|
| Biocompatible Materials | 3 | 2005 | 114 | 0.120 |
Why?
|
| Nitric Oxide | 1 | 2014 | 101 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 8 | 0.120 |
Why?
|
| Titanium | 3 | 2001 | 209 | 0.120 |
Why?
|
| Rheumatoid Factor | 2 | 2011 | 9 | 0.120 |
Why?
|
| Antibodies | 4 | 2004 | 65 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2013 | 17 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2013 | 153 | 0.120 |
Why?
|
| Biotransformation | 1 | 2013 | 7 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 8 | 0.120 |
Why?
|
| Oligosaccharides | 2 | 2012 | 17 | 0.120 |
Why?
|
| Immunodominant Epitopes | 1 | 2013 | 3 | 0.120 |
Why?
|
| Achilles Tendon | 1 | 2013 | 18 | 0.120 |
Why?
|
| Genetic Linkage | 4 | 2009 | 65 | 0.110 |
Why?
|
| Cell Communication | 2 | 2004 | 29 | 0.110 |
Why?
|
| Chromosomes | 1 | 2012 | 2 | 0.110 |
Why?
|
| Genotype | 2 | 2005 | 405 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2014 | 394 | 0.110 |
Why?
|
| Mice, Inbred C3H | 5 | 2004 | 33 | 0.110 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2012 | 4 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2012 | 5 | 0.110 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2009 | 24 | 0.110 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 27 | 0.110 |
Why?
|
| Eosinophilia | 1 | 2012 | 47 | 0.110 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2011 | 10 | 0.110 |
Why?
|
| Alleles | 1 | 2012 | 224 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 32 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 33 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2009 | 83 | 0.110 |
Why?
|
| Injections, Intra-Articular | 1 | 2012 | 88 | 0.110 |
Why?
|
| Bone Resorption | 3 | 2008 | 104 | 0.110 |
Why?
|
| Wound Healing | 1 | 2013 | 168 | 0.110 |
Why?
|
| Cell Separation | 2 | 2011 | 42 | 0.110 |
Why?
|
| Interleukin-2 | 5 | 2007 | 66 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2012 | 61 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Metals | 2 | 2005 | 160 | 0.100 |
Why?
|
| Homeostasis | 1 | 2012 | 82 | 0.100 |
Why?
|
| Lung | 1 | 2012 | 154 | 0.100 |
Why?
|
| Species Specificity | 6 | 2012 | 70 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2012 | 112 | 0.100 |
Why?
|
| Cricetulus | 1 | 2011 | 13 | 0.100 |
Why?
|
| Fibrinolysin | 1 | 2011 | 5 | 0.100 |
Why?
|
| CHO Cells | 1 | 2011 | 12 | 0.100 |
Why?
|
| Crosses, Genetic | 4 | 2008 | 13 | 0.100 |
Why?
|
| Cricetinae | 1 | 2011 | 36 | 0.100 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2011 | 2 | 0.100 |
Why?
|
| Biomarkers | 3 | 2011 | 689 | 0.100 |
Why?
|
| Interleukins | 1 | 2011 | 37 | 0.100 |
Why?
|
| HLA-DQ Antigens | 2 | 2016 | 7 | 0.100 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 668 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2011 | 495 | 0.100 |
Why?
|
| Stifle | 1 | 2010 | 11 | 0.100 |
Why?
|
| Cell Death | 1 | 2010 | 61 | 0.100 |
Why?
|
| Antigens | 4 | 2004 | 26 | 0.100 |
Why?
|
| Spondylitis | 1 | 1990 | 3 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2006 | 1113 | 0.100 |
Why?
|
| Time Factors | 4 | 2012 | 1616 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2011 | 321 | 0.100 |
Why?
|
| Streptococcus pyogenes | 1 | 2010 | 5 | 0.090 |
Why?
|
| RNA, Messenger | 6 | 2002 | 323 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 8 | 0.090 |
Why?
|
| Gene Knock-In Techniques | 1 | 2010 | 9 | 0.090 |
Why?
|
| Sphingosine | 1 | 2010 | 4 | 0.090 |
Why?
|
| Propylene Glycols | 1 | 2010 | 4 | 0.090 |
Why?
|
| Monocytes | 2 | 2001 | 116 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 2010 | 14 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2010 | 264 | 0.090 |
Why?
|
| Glioma | 1 | 2010 | 47 | 0.090 |
Why?
|
| HLA-B27 Antigen | 1 | 2009 | 2 | 0.090 |
Why?
|
| Chromosome Mapping | 4 | 2012 | 52 | 0.090 |
Why?
|
| Interleukin-6 | 2 | 2008 | 108 | 0.090 |
Why?
|
| Peptides | 1 | 2010 | 95 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2023 | 146 | 0.090 |
Why?
|
| Ligands | 4 | 2003 | 55 | 0.090 |
Why?
|
| Glucosamine | 1 | 2009 | 9 | 0.090 |
Why?
|
| Penetrance | 1 | 2009 | 3 | 0.090 |
Why?
|
| Macrophages | 1 | 2010 | 128 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 124 | 0.090 |
Why?
|
| In Situ Hybridization | 3 | 2009 | 46 | 0.090 |
Why?
|
| Transfection | 3 | 2011 | 125 | 0.090 |
Why?
|
| Hip Prosthesis | 3 | 2000 | 605 | 0.080 |
Why?
|
| Cross Reactions | 5 | 2003 | 26 | 0.080 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 7 | 0.080 |
Why?
|
| Incidence | 4 | 2005 | 756 | 0.080 |
Why?
|
| Blood Platelets | 1 | 2008 | 49 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2008 | 9 | 0.080 |
Why?
|
| Osteoclasts | 1 | 2008 | 19 | 0.080 |
Why?
|
| Bone Remodeling | 1 | 2008 | 44 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2017 | 3478 | 0.080 |
Why?
|
| Fetus | 2 | 1998 | 56 | 0.080 |
Why?
|
| Osteoblasts | 1 | 2008 | 63 | 0.080 |
Why?
|
| Collagen Type II | 3 | 2003 | 31 | 0.080 |
Why?
|
| Cell Line | 3 | 2005 | 298 | 0.080 |
Why?
|
| CD28 Antigens | 2 | 2004 | 16 | 0.080 |
Why?
|
| Knee Joint | 4 | 2009 | 797 | 0.080 |
Why?
|
| Metalloendopeptidases | 4 | 2001 | 24 | 0.080 |
Why?
|
| Liver | 1 | 2009 | 173 | 0.080 |
Why?
|
| Models, Animal | 2 | 2005 | 126 | 0.080 |
Why?
|
| Osteoarthritis, Knee | 1 | 2012 | 381 | 0.080 |
Why?
|
| Sheep | 2 | 2004 | 39 | 0.080 |
Why?
|
| Swine | 2 | 2004 | 80 | 0.080 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2007 | 6 | 0.080 |
Why?
|
| Tryptophan | 1 | 2007 | 15 | 0.070 |
Why?
|
| Collagenases | 2 | 1996 | 20 | 0.070 |
Why?
|
| Histocompatibility Antigens | 1 | 1986 | 3 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2003 | 24 | 0.070 |
Why?
|
| Intervertebral Disc | 3 | 2005 | 212 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 145 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2005 | 15 | 0.070 |
Why?
|
| Ovalbumin | 1 | 2005 | 8 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 324 | 0.070 |
Why?
|
| Antibody Formation | 4 | 2012 | 40 | 0.070 |
Why?
|
| Cell Transplantation | 1 | 2005 | 29 | 0.070 |
Why?
|
| Sacroiliac Joint | 1 | 2005 | 9 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 20 | 0.070 |
Why?
|
| fas Receptor | 2 | 2003 | 11 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 36 | 0.060 |
Why?
|
| Immunity, Cellular | 5 | 2012 | 65 | 0.060 |
Why?
|
| Aged | 8 | 2012 | 9448 | 0.060 |
Why?
|
| HLA-DR4 Antigen | 1 | 2004 | 2 | 0.060 |
Why?
|
| Serum Albumin, Bovine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2004 | 3 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 75 | 0.060 |
Why?
|
| Mice, Inbred AKR | 1 | 2004 | 2 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2004 | 28 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 35 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2004 | 63 | 0.060 |
Why?
|
| Prostheses and Implants | 1 | 2005 | 166 | 0.060 |
Why?
|
| Blood Proteins | 2 | 2001 | 20 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 218 | 0.060 |
Why?
|
| Alloys | 2 | 2001 | 102 | 0.060 |
Why?
|
| Ovary | 1 | 2003 | 17 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 10 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 31 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2000 | 44 | 0.060 |
Why?
|
| CD4 Antigens | 1 | 2003 | 35 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 58 | 0.060 |
Why?
|
| Genetic Markers | 3 | 2012 | 58 | 0.060 |
Why?
|
| X-Ray Microtomography | 1 | 2023 | 72 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 32 | 0.060 |
Why?
|
| Animals, Newborn | 1 | 2002 | 55 | 0.060 |
Why?
|
| Polymorphism, Genetic | 3 | 2013 | 78 | 0.060 |
Why?
|
| Genome | 3 | 2012 | 15 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2002 | 38 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2013 | 159 | 0.050 |
Why?
|
| ADAMTS5 Protein | 2 | 2013 | 27 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 116 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 145 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1985 | 202 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2013 | 301 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 170 | 0.050 |
Why?
|
| Protein Binding | 4 | 2003 | 127 | 0.050 |
Why?
|
| Genes, myc | 1 | 2001 | 6 | 0.050 |
Why?
|
| Hydrolysis | 1 | 2001 | 9 | 0.050 |
Why?
|
| ADAM17 Protein | 1 | 2001 | 3 | 0.050 |
Why?
|
| Absorbable Implants | 1 | 2001 | 24 | 0.050 |
Why?
|
| Genes, ras | 1 | 2001 | 13 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 17 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2001 | 37 | 0.050 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2000 | 8 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2017 | 45 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2001 | 105 | 0.050 |
Why?
|
| Aging | 2 | 2010 | 1593 | 0.050 |
Why?
|
| Contraindications | 1 | 2000 | 41 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2000 | 21 | 0.050 |
Why?
|
| Cobalt | 1 | 2001 | 116 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 254 | 0.050 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2000 | 21 | 0.050 |
Why?
|
| Mice, Congenic | 2 | 2012 | 4 | 0.050 |
Why?
|
| Reference Values | 2 | 1998 | 227 | 0.050 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2000 | 5 | 0.050 |
Why?
|
| Mitochondria | 1 | 2000 | 78 | 0.050 |
Why?
|
| Actins | 1 | 2000 | 45 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 306 | 0.050 |
Why?
|
| Drug Synergism | 3 | 2004 | 63 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2000 | 113 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2019 | 18 | 0.040 |
Why?
|
| Chromium | 1 | 2000 | 92 | 0.040 |
Why?
|
| Immunophenotyping | 4 | 2004 | 80 | 0.040 |
Why?
|
| Hybrid Cells | 1 | 1999 | 9 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 1 | 2019 | 3 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 1996 | 78 | 0.040 |
Why?
|
| Base Sequence | 3 | 2011 | 134 | 0.040 |
Why?
|
| Carbohydrate Sequence | 1 | 1998 | 13 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 2010 | 28 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 188 | 0.040 |
Why?
|
| Acute Disease | 3 | 2004 | 226 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 3 | 2002 | 8 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 2017 | 15 | 0.040 |
Why?
|
| Protein Transport | 1 | 2017 | 38 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1988 | 78 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2017 | 36 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2017 | 78 | 0.040 |
Why?
|
| Knee Prosthesis | 1 | 2000 | 248 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 3 | 2001 | 13 | 0.040 |
Why?
|
| Cardiac Myosins | 1 | 2016 | 2 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2017 | 107 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 20 | 0.040 |
Why?
|
| Clone Cells | 2 | 2003 | 20 | 0.040 |
Why?
|
| Pneumonia | 1 | 2017 | 67 | 0.040 |
Why?
|
| Adolescent | 3 | 1998 | 2279 | 0.030 |
Why?
|
| Chickens | 1 | 1995 | 20 | 0.030 |
Why?
|
| Mice, Nude | 1 | 1995 | 33 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 22 | 0.030 |
Why?
|
| Immunochemistry | 1 | 1995 | 5 | 0.030 |
Why?
|
| Carbohydrates | 2 | 2012 | 14 | 0.030 |
Why?
|
| Immunotherapy | 1 | 1995 | 62 | 0.030 |
Why?
|
| Chromatin | 1 | 2014 | 15 | 0.030 |
Why?
|
| Osteolysis | 1 | 1995 | 149 | 0.030 |
Why?
|
| Biological Factors | 1 | 2014 | 9 | 0.030 |
Why?
|
| Solubility | 2 | 2005 | 36 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 5 | 0.030 |
Why?
|
| Chemokines | 2 | 2004 | 29 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1994 | 298 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 18 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2013 | 4 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2013 | 4 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 9 | 0.030 |
Why?
|
| Collagen Type III | 1 | 2013 | 13 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2013 | 7 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 18 | 0.030 |
Why?
|
| Integrins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2013 | 19 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 24 | 0.030 |
Why?
|
| Histones | 1 | 2013 | 28 | 0.030 |
Why?
|
| Hindlimb | 2 | 2003 | 23 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 47 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 6 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 50 | 0.030 |
Why?
|
| Electrophoresis | 1 | 2012 | 15 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2012 | 3 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 2 | 2003 | 10 | 0.030 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2012 | 2 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2012 | 15 | 0.030 |
Why?
|
| Transcriptome | 1 | 2013 | 83 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2012 | 11 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2012 | 17 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2012 | 81 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 90 | 0.030 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 2 | 2003 | 4 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 22 | 0.030 |
Why?
|
| Fas Ligand Protein | 2 | 2003 | 9 | 0.030 |
Why?
|
| Smoking | 1 | 2013 | 194 | 0.030 |
Why?
|
| Isoxazoles | 1 | 1992 | 16 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 65 | 0.030 |
Why?
|
| Weight-Bearing | 1 | 2012 | 164 | 0.030 |
Why?
|
| Rheumatology | 1 | 2013 | 81 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 21 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2012 | 23 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 35 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 28 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 127 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2000 | 863 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2011 | 2 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 24 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2003 | 97 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2003 | 101 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 28 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 47 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 64 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2011 | 4 | 0.030 |
Why?
|
| Exons | 1 | 2011 | 34 | 0.030 |
Why?
|
| Homozygote | 1 | 2011 | 23 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2011 | 25 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2011 | 28 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 40 | 0.020 |
Why?
|
| Chondroitin | 1 | 2010 | 6 | 0.020 |
Why?
|
| Versicans | 1 | 2010 | 15 | 0.020 |
Why?
|
| Arthralgia | 1 | 2012 | 121 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 39 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2010 | 7 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 103 | 0.020 |
Why?
|
| Asthma | 1 | 2012 | 138 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 1990 | 18 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2010 | 13 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 100 | 0.020 |
Why?
|
| Peritoneal Lavage | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2009 | 8 | 0.020 |
Why?
|
| Peritoneum | 1 | 2009 | 18 | 0.020 |
Why?
|
| Joint Diseases | 1 | 1990 | 110 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 3 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 1998 | 4851 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 55 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 17 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2008 | 46 | 0.020 |
Why?
|
| Bone and Bones | 2 | 2005 | 119 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 102 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 437 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 123 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1987 | 13 | 0.020 |
Why?
|
| Kynuramine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 36 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2007 | 15 | 0.020 |
Why?
|
| DNA | 1 | 1987 | 125 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 1986 | 604 | 0.020 |
Why?
|
| Radiography | 2 | 2005 | 678 | 0.020 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 1996 | 7 | 0.020 |
Why?
|
| Immune Sera | 1 | 1986 | 9 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1442 | 0.020 |
Why?
|
| Larynx | 1 | 1986 | 16 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 45 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2005 | 16 | 0.020 |
Why?
|
| Hybridization, Genetic | 1 | 2005 | 3 | 0.020 |
Why?
|
| Cell Shape | 1 | 2005 | 8 | 0.020 |
Why?
|
| Necrosis | 1 | 2005 | 26 | 0.020 |
Why?
|
| Stimulation, Chemical | 2 | 1995 | 14 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 148 | 0.020 |
Why?
|
| Abatacept | 1 | 2004 | 8 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2004 | 12 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 14 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2004 | 6 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 2004 | 10 | 0.020 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 1985 | 10 | 0.020 |
Why?
|
| Cell Survival | 1 | 2005 | 169 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2004 | 12 | 0.020 |
Why?
|
| Fibronectins | 1 | 1985 | 29 | 0.020 |
Why?
|
| Materials Testing | 1 | 2005 | 137 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2004 | 99 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2003 | 2 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 26 | 0.010 |
Why?
|
| Lod Score | 1 | 2003 | 22 | 0.010 |
Why?
|
| X Chromosome | 1 | 2003 | 9 | 0.010 |
Why?
|
| STAT4 Transcription Factor | 1 | 2002 | 1 | 0.010 |
Why?
|
| Self Tolerance | 1 | 2002 | 2 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2002 | 26 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 12 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 29 | 0.010 |
Why?
|
| Immunity, Mucosal | 1 | 2002 | 29 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2001 | 29 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 2001 | 12 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 71 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 496 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2001 | 35 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2000 | 6 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2000 | 6 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 30 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 32 | 0.010 |
Why?
|
| Caspase 1 | 1 | 2000 | 14 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 138 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 109 | 0.010 |
Why?
|
| Plasma Cells | 1 | 2000 | 8 | 0.010 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2000 | 27 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2000 | 213 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 3 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1999 | 4 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1999 | 7 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1999 | 7 | 0.010 |
Why?
|
| Lymphotoxin-alpha | 1 | 1999 | 6 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2000 | 189 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1996 | 642 | 0.010 |
Why?
|
| Spine | 1 | 2001 | 121 | 0.010 |
Why?
|
| Corrosion | 1 | 2000 | 139 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 107 | 0.010 |
Why?
|
| Child | 2 | 1996 | 1346 | 0.010 |
Why?
|
| Serine | 1 | 1997 | 11 | 0.010 |
Why?
|
| Endothelium | 1 | 1997 | 12 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 28 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1996 | 26 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 26 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1995 | 2 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1995 | 15 | 0.010 |
Why?
|
| Chloroquine | 1 | 1995 | 12 | 0.010 |
Why?
|
| Biological Transport | 1 | 1995 | 43 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 1995 | 15 | 0.010 |
Why?
|
| Temperature | 1 | 1995 | 76 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1995 | 13 | 0.010 |
Why?
|
| Movement | 1 | 1993 | 143 | 0.010 |
Why?
|
| Pepsin A | 1 | 1990 | 2 | 0.010 |
Why?
|
| Growth Plate | 1 | 1990 | 23 | 0.010 |
Why?
|
| Gait | 1 | 1993 | 404 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1987 | 56 | 0.000 |
Why?
|
| Chromatography, Affinity | 1 | 1986 | 9 | 0.000 |
Why?
|
| Amino Acids | 1 | 1986 | 20 | 0.000 |
Why?
|
| Borohydrides | 1 | 1986 | 2 | 0.000 |
Why?
|
| Alkalies | 1 | 1986 | 3 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1985 | 20 | 0.000 |
Why?
|
| Infant | 1 | 1986 | 531 | 0.000 |
Why?
|
| Age Factors | 1 | 1986 | 843 | 0.000 |
Why?
|
| Lumbar Vertebrae | 1 | 1987 | 487 | 0.000 |
Why?
|